Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vigil Neuroscience, Inc.

2.02
-0.0900-4.27%
Post-market: 2.030.0100+0.50%19:32 EDT
Volume:78.36K
Turnover:162.86K
Market Cap:94.28M
PE:-0.98
High:2.18
Open:2.12
Low:2.02
Close:2.11
Loading ...

Vigil likely to land Alzheimer’s deal after today’s data, says Mizuho

TIPRANKS
·
24 Jan

Vigil Neuroscience Shares up 12.3% After Early-Stage Study Data on Alzheimer's Drug

THOMSON REUTERS
·
23 Jan

BUZZ-Vigil Neuroscience rises on early-stage Alzheimer's drug trial data

Reuters
·
23 Jan

Traders Cautious Ahead of Jobless Numbers, Flood of Earnings Reports

MT Newswires Live
·
23 Jan

BRIEF-Vigil Neuroscience Reports Positive Data From Its Phase 1 Clinical Trial

Reuters
·
23 Jan

Vigil Neuroscience Inc - Vg-3927 Showed Favorable Safety and Tolerability Profile

THOMSON REUTERS
·
23 Jan

Vigil Neuroscience Reports Positive Data From Its Phase 1 Clinical Trial Evaluating Vg-3927 for the Potential Treatment of Alzheimer’s Disease

THOMSON REUTERS
·
23 Jan

Vigil Neuroscience Inc - Vg-3927 to Advance to Phase 2 Trial in Q3 2025

THOMSON REUTERS
·
23 Jan

Vigil Neuroscience Inc - Vg-3927 Achieved up to 50% Reduction of Strem2 in Csf

THOMSON REUTERS
·
23 Jan

Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease

GlobeNewswire
·
23 Jan

Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN), Trevi Therapeutics (TRVI) and Vigil Neuroscience Inc (VIGL)

TIPRANKS
·
05 Dec 2024

William Blair Initiates Vigil Neuroscience at Outperform

MT Newswires Live
·
04 Dec 2024

Vigil Neuroscience Inc : William Blair Initiates Coverage With Outperform Rating; Fair Value Estimate $18.67

THOMSON REUTERS
·
04 Dec 2024

Vigil Neuroscience initiated with an Outperform at William Blair

TIPRANKS
·
04 Dec 2024

Vigil Neuroscience Initiated at Outperform by William Blair

Dow Jones
·
04 Dec 2024

Analysts Offer Insights on Healthcare Companies: IN8bio (INAB), Vigil Neuroscience Inc (VIGL) and Outlook Therapeutics (OTLK)

TIPRANKS
·
28 Nov 2024